Cover Image
市場調查報告書

Sangamo BioSciences, Inc.的產品平台分析

Sangamo BioSciences, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 192814
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
Sangamo BioSciences, Inc.的產品平台分析 Sangamo BioSciences, Inc. - Product Pipeline Review - 2016
出版日期: 2016年06月08日 內容資訊: 英文 55 Pages
簡介

Sangamo BioSciences, Inc.是研究開發調節遺傳基因及編輯基因用新DNA結合蛋白的臨床階段生物醫藥品公司。

本報告提供Sangamo BioSciences, Inc.的治療藥開發平台現況及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Sangamo BioSciences, Inc.的基本資料

  • Sangamo BioSciences, Inc.概要
  • 主要資訊
  • 企業資料

Sangamo BioSciences, Inc.:R&D概要

  • 主要的治療範圍

Sangamo BioSciences, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Sangamo BioSciences, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Sangamo BioSciences, Inc.:藥物簡介

  • CERE-110
  • SB-728T
  • Stem Cell Therapy to Activate CCR5 for HIV
  • Gene Therapy for Hemophilia A
  • Gene Therapy for Huntington's Disease
  • Gene Therapy for Lung Diseases
  • Gene Therapy for Sickle Cell Disease
  • Gene Therapy for X-Linked SCID
  • Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency
  • SB-318
  • SB-728
  • SB-913
  • SBLSD-3
  • SBLSD-4
  • SHP-624
  • Stem Cell Therapy for Beta Thalassemia
  • Stem Cell Therapy to Activate CXCR4 for HIV
  • Gene Therapy for Monogenic Diseases

Sangamo BioSciences, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sangamo BioSciences, Inc.:最近的開發平台趨勢

Sangamo BioSciences, Inc.:暫停中的計劃

Sangamo BioSciences, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • SB-509

Sangamo BioSciences, Inc.:企業發表

Sangamo BioSciences, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08065CDB

Summary

Global Markets Direct's, 'Sangamo BioSciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Sangamo BioSciences, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sangamo BioSciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sangamo BioSciences, Inc.
  • The report provides overview of Sangamo BioSciences, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sangamo BioSciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sangamo BioSciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sangamo BioSciences, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sangamo BioSciences, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sangamo BioSciences, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sangamo BioSciences, Inc. Snapshot
    • Sangamo BioSciences, Inc. Overview
    • Key Information
    • Key Facts
  • Sangamo BioSciences, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sangamo BioSciences, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Sangamo BioSciences, Inc. - Pipeline Products Glance
    • Sangamo BioSciences, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sangamo BioSciences, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sangamo BioSciences, Inc. - Drug Profiles
    • SB-728T
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-728HSPC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-FIX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-318
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Beta Thalassemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Sickle Cell Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for X-Linked SCID
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Active Pulmonary Surfactant-Associated Protein B for Lung Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Inhibit Huntingtin Protein for Huntington's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-913
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-FVIII
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBLSD-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBLSD-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Monogenic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sangamo BioSciences, Inc. - Pipeline Analysis
    • Sangamo BioSciences, Inc. - Pipeline Products by Target
    • Sangamo BioSciences, Inc. - Pipeline Products by Route of Administration
    • Sangamo BioSciences, Inc. - Pipeline Products by Molecule Type
    • Sangamo BioSciences, Inc. - Pipeline Products by Mechanism of Action
  • Sangamo BioSciences, Inc. - Recent Pipeline Updates
  • Sangamo BioSciences, Inc. - Dormant Projects
  • Sangamo BioSciences, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CERE-110
      • CERE-120
      • SB-509
  • Sangamo BioSciences, Inc. - Company Statement
  • Sangamo BioSciences, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sangamo BioSciences, Inc., Key Information
  • Sangamo BioSciences, Inc., Key Facts
  • Sangamo BioSciences, Inc. - Pipeline by Indication, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Stage of Development, 2016
  • Sangamo BioSciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Sangamo BioSciences, Inc. - Phase II, 2016
  • Sangamo BioSciences, Inc. - Phase I, 2016
  • Sangamo BioSciences, Inc. - IND/CTA Filed, 2016
  • Sangamo BioSciences, Inc. - Preclinical, 2016
  • Sangamo BioSciences, Inc. - Discovery, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Target, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Route of Administration, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Molecule Type, 2016
  • Sangamo BioSciences, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Sangamo BioSciences, Inc. - Recent Pipeline Updates, 2016
  • Sangamo BioSciences, Inc. - Dormant Developmental Projects,2016
  • Sangamo BioSciences, Inc. - Discontinued Pipeline Products, 2016
  • Sangamo BioSciences, Inc., Subsidiaries

List of Figures

  • Sangamo BioSciences, Inc. - Pipeline by Top 10 Indication, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Stage of Development, 2016
  • Sangamo BioSciences, Inc. - Monotherapy Products in Pipeline, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Target, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Route of Administration, 2016
  • Sangamo BioSciences, Inc. - Pipeline by Molecule Type, 2016
  • Sangamo BioSciences, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top